entertainment
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.
Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.
advertisement
This is a familiar but tiring refrain.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Head of FDA's diagnostics center, who led through Covid, retires
Next article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： BioMarin wins approval for gene therapy to treat hemophilia A
